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Abstract
Background: The aim of this study was to investigate prognostic value of excision repair cross-complementing 1
(ERCC1), BCL2-associated athanogene (BAG-1), the breast and ovarian cancer susceptibility gene 1 (BRCA1),
ribonucleotide reductase subunit M1 (RRM1) and class III b-tubulin (TUBB3) in patients with non-small cell lung
cancer (NSCLC) who received platinum- based adjuvant chemotherapy.
Methods: Messenger RNA expressions of these genes were examined in 85 tumor tissues and 34 adjacent tissue
samples using semi-quantitative RT-PCR. The expressions of these five genes were analyzed in relation to
chemotherapy and progression-free survival (PFS) and overall survival (OS). Seventy-four patients were enrolled into
chemotherapy.
Results: Patients with ERCC1 or BAG-1 negative expression had a significantly longer PFS (P = 0.001 and P = 0.001)
and OS (P = 0.001 and P = 0.001) than those with positive expression. Patients with negative ERCC1 and BAG-1
expression benefited more from platinum regimen (P = 0.001 and P = 0.002). Patients with BRCA1 negative
expression might have a longer OS (P = 0.052), but not PFS (P = 0.088) than those with BRCA1 positive expression.
A significant relationship was observed between the mRNA expression of ERCC1 and BAG-1 (P = 0.042). In
multivariate analysis, ERCC1 and BAG-1 were significantly favorable factors for PFS (P = 0.018 and P = 0.017) and OS
(P = 0.027 and P = 0.022).
Conclusions: ERCC1 and BAG-1 are determinants of survival after surgical treatment of NSCLC, and its mRNA
expression in tumor tissues could be used to predict the prognosis of NSCLC treated by platinum.
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Background
Lung cancer is a common malignant tumor, and was the
first ranked cause of cancer death in both males and
females [1]. As one of the most prevalent malignant
tumors in China, lung cancer has been highlighted with
emphasis for cancer prevention and treatment. Recently,
the combinations of cytotoxic agents (such as gemcita-
bine, vinorelbine, and taxane) and platinum become
new standard for non-small-cell lung cancer (NSCLC).
But the resistance to these drugs causes unsatisfactory
of overall survival rate. Therefore, it is very important to
understand the molecular markers of resistance to che-
motherapeutic drugs.
The excision repair cross-complementing 1 (ERCC1) is a
DNA damage repair gene that encodes the 5’ endonu-
clease of the NER complex, and is one of the key enzymes
of the nucleotide excision repair (NER) pathway which is
essential for the removal of platinum-DNA adducts. Clini-
cal studies have found that high ERCC1 expression is asso-
ciated with resistance to platinum-based chemotherapy
and worse prognosis in patients with advanced NSCLC
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any medium, provided the original work is properly cited.[2]. The human BAG-1 gene is located in chromosome 9
and encodes three major BAG-1 isoforms, BAG-1S (p36),
BAG-1 M (p46), and BAG-1 L (p50), which are generated
via alternate translation mechanisms from the same
mRNA [3]. BAG-1 is a multifunctional binding protein
involved in differentiation, cell cycle, and apoptosis. BAG-
1 has recently been found to bind and interact with the
anti-apoptotic gene Bcl-2, thereby inhibiting apoptosis [4].
Because of its affect on apoptosis, BAG-1 may play an
important role in lung cancer. Further study showed that
BAG-1 could be a target for lung cancer treatment of cis-
platin [5]. The breast and ovarian cancer susceptibility
gene1 (BRCA1) was the first breast cancer susceptibility
gene identified in 1990 and was primary cloned in 1994. It
has multiple roles not only in DNA damage repair but
also in cell cycle regulation, transcriptional control, ubiqui-
tination and apoptosis. In NSCLC, chemotherapeutic
treatment can damage DNA through various mechanisms,
the lack of functional BRCA1 can lead to increased sensi-
tivity of the tumor cells to molecular damage, demonstrat-
ing that BRCA1 represents a predictive marker of
chemotherapy response in NSCLC [6].
Ribonucleotide reductase subunit M1 (RRM1) is
located on chromosome segment 11p15.5, it is a region
with a frequent loss of heterozygosity in NSCLC. It is a
component of ribonucleotide reductase, which is
required for deoxynucleotide production and is also the
predominant cellular determinant of the efficacy of gem-
citabine, which make it to be the molecular target of
gemcitabine [7,8]. Along with the use of antitubulin
agents such as taxanes and vinorelbine, study shows
there are a number of tubulin isotypes in humans, and
f o u n dt h a tc l a s sI I Ib-tubulin (TUBB3) among them is
expressed in a proportion and related to clinical out-
come [9]. The expression of TUBB3 is associated with
resistance of paclitaxel and docetaxel, no matter in vitro
or in clinical research [10,11].
Changes of gene mRNA expression during carcinogen-
esis may lead impact of the diagnosis, treatment, and pre-
vention of NSCLC, it is important to understand these
changes. So, in this study, we use RT-PCR to examine the
expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3
in tumor samples from patients with resected NSCLC not
receiving adjuvant chemotherapy. We analyzed the rela-
tionships of these genes expression in tumors about survi-
val time and response to chemotherapy to determine
whether the expression of these molecules could be used
as prognostic factors of progression-free and overall survi-
val in this cohort of patients.
Methods
Patient data
A total of 85 patients who underwent curative surgery
for NSCLC between August 2007 and April 2009 were
enrolled into this study, including 85 tumor tissues and
34 adjacent tissues respectively. Among them there were
60 males and 25 females, aged 24-84 (mean 57) years.
According to WHO Classification (2000), there were 25
squamous, 60 adenomatous, with 58 moderate and well
differentiated (G1-G2) and 27 low differentiated (G3).
Because there were only 4 cases of stage IV patients
who all had surgery after single brain metastasis
resected firstly, and there were no patients of stage IIIb.
On account of stage IV patients were too few, so we
combined 48 cases as staged I-II and 37 III-IV based on
the revised AJC staging for lung cancer (1997). 28 cases
had intra-thoracic lymph node metastasis (N1-N2), and
57 were negative lymph node metastasis. Additional
information of surgery and chemotherapy status were all
showed in (Table 1). The paracancerous tissues (defined
as more than 5 cm away from the carcinoma tissue)
taken from 34 cases were used as controls. A total of 74
Patients received at least two cycles of adjuvant che-
motherapy within three months after surgery in the
First Afflicted Hospital of Guangxi Medical University.
34 of 74 patients were received GP (Cisplatin 75 mg/m
2
on day 1, Gemcitabine 1000 mg/m
2 on days 1,8), 29 of
74 patients were received NP (Cisplatin 75 mg/m
2 on
day 1, Vinorelbine 25 mg/m
2 on days 1 + 8), the other
11 patients were received TP (Carboplatin AUC 6 on
day 1, Paclitaxel 175 mg/m
2 on day 1), every 3 weeks.
All of the tumor tissue samples were freshly frozen in
liquid nitrogen immediately after surgery, and stored at
-80
0 C until analysis was available. We took out the
specimens from the parenchymal tissues of tumor, and
we must as far as possible make the specimens keep
away from the necrotic tissue. We also confirmed the
HE stain results from the pathology department after
surgery, which tumor sections, from the location speci-
mens taken by us, were full of tumor cells (usually more
than 60%-70%). Patients who received neoadjuvant che-
motherapy or neoadjuvant radiotherapy were excluded.
The study protocol was approved by the Ethical Com-
mittee of the First Affiliated Hospital of Guangxi Medi-
cal University, China. All subjects signed an informed
consent before entry into the study.
RNA isolation and cDNA synthesis
Fresh frozen specimens of tumor and adjacent tissues
were obtained from 85 patients. Collection time from
resection to freezing was required 20 minutes or less
for all specimens. The fresh frozen specimens were
processed for RNA isolation and reverse-transcriptase
polymerase chain reaction (RT-PCR) in detecting
expression analysis for the ERCC1, BAG-1, BRCA1,
RRM1, and TUBB3 genes. Specimens were microscopi-
cally examined to assess quality and to verify the
histopathology.
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zol reagent (Invitrogen). Total RNA was extracted with
Trizol reagent and dissolved in DEPC water. Total RNA
were reverse transcribed with RevertAid™ First Strand
cDNA Synthesis Kit (Fermentas) for generation of
cDNA. Gene expression for ERCC1, BAG-1, BRCA1,
TUBB3, RRM1 and b-actin (internal reference gene)
were performed using RT-PCR. The preliminary experi-
ment and large sample experiment PCR were carried
out as follows: an initial denaturation at 94°C for 3 min
30 s, followed by 30 cycles of denaturation at 94°C for
40 s, annealing at different temperature for different
gene for 40 s, and elongation at 72°C for 50 s, then
elongation 72°C for 7 min at last. The sequences of the
primers used were in Table 2. All of these primers were
checked and met a high specificity by BLAST function
in NCBI. Confirmative PCR products through gene
sequencing were used as positive controls to exclude
false negative, and the no template added reaction sys-
tem used as negative controls to exclude contamination
of genomic DNA (Figure 1).
Statistical analysis
The data were analyzed using SPSS 17.0 software pack-
age. The correlation of gene expression with different
clinical characteristics was analyzed with chi-square test
or Fisher’s exact test. Correlation between gene mRNA
levels was evaluated by Spearman correlation coeffi-
cients. The Kaplan-Meier method and Log-rank test
were used to analyze the correlation of patient survival
with gene expression. Factors with significant influence
on survival in univariate analysis were further analyzed
by multivariate Cox regression analysis. A significance
level of P < 0.05 was used.
Results
Expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3
mRNA after surgical resection
Tumor specimens from 85 patients were available for
the analysis of these genes mRNA. The specimens
included 85 tumor tissues and 34 adjacent tissues. The
positive rate of ERCC1 mRNA in tumor and its adjacent
tissues were 58.8% and 55.9% respectively (P = 0.769).
BAG-1 were 37.6% and 82.4% (P = 0.000). BRCA1 were
16.5% and 44.1% (P = 0.002). RRM1 were 30.8% and
38.2% (P = 0.105). TUBB3 were 16.5% and 2.9% (P =
0.089). We chose some of the same samples which
ERCC1 mRNA expressions were positive in order to
validate the results. Expression of ERCC1 proteins was
assessed by immunohistochemistry, and expression of
the ERCC1 proteins was detected in the nuclei of cancer
cells. All the samples selected were ERCC1 positive,
including 6 squamous carcinoma and 6 adenocarcinoma
(Figure 2).
Correlation between ERCC1, BAG-1, BRCA1, RRM1 and
TUBB3 expression and clinical features
The expression of five genes in different clinical fea-
tures were compared and summarized. It showed that
the difference of these five genes were only significant
between some parts of clinical features. Correlations
were observed between ERCC1 expression and TNM
stage (P = 0.006), metastasis of lymph node (P =0 . 0 1 ) ,
and TUBB3 expression and TNM stage (P = 0.004).
No Correlation was observed between ERCC1, TUBB3
expression and other clinical features. Besides, No
Correlation was observed between BAG-1, BRCA1,
RRM1 expression and gender, age, nationality, histol-
ogy, differentiation of tumor, metastasis of lymph
node, TNM stage, chemotherapy status or perfor-
mance status.
Table 1 Baseline characteristics of 85 patients with
NSCLC
Characteristics Number Percentage (%)
Gender
Male 60 70.6
Female 25 29.4
Age
≤ 60 53 62.4
> 60 32 37.6
Nationality
The Han 60 70.6
The Zhuang 25 29.4
Histology
Squamous carcinoma 25 29.4
Adenocarcinoma 60 70.6
Differentiation
Well and moderate 58 68.2
Poor 27 31.8
Metastasis lymphatics
Yes 28 32.9
No 57 67.1
TNM stage
I + II 48 56.5
III + IV 37 43.5
Surgery status
Lobectomy 79 92.9
Pneumonectomy 6 7.1
Chemotherapy status(74 cases)
GP regimens 34 45.9
NP regimens 29 39.2
TP regimens 11 14.9
ECOG Performance status
0 22 25.9
1 63 74.1
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surgical resection
The median follow-up time was 23.3 months (range 2.3-
42.6), and the median overall survival and median PFS
(progression-free survival) were 27.2 months (range 2.3-
42.6) and 26.5 months (range 0.8-42.6), respectively. Fig-
ures 3, 4, 5 and 6 showed the Kaplan-Meier survival
curves in patients positive and negative for ERCC1 and
BAG-1 expression. Patients negative for ERCC1 expres-
sion had a significantly longer median progression-free
(more than 42.6 vs. 15.4 months. P = 0.001) and overall
(more than 42.6 vs. 20.9 months. P = 0.001) survival,
compared with those positive for ERCC1 expression.
Patients negative for BAG-1 expression had a signifi-
cantly longer median progression-free survival (more
than 42.6 vs. 12.9 months. P = 0.001) and overall survi-
val (more than 42.6 vs. 17.0 months. P = 0.001), than
those positive for BAG-1 expression. The relationships
between the PFS and BRCA1, RRM1 and TUBB3 were
no statistical significance (P = 0.088, P = 0.116 and P =
0.271), and there were also the same results for OS (P =
0.057, P = 0.110 and P = 0.342).
Median value of clinicopathologic factors and expres-
sion of genes of tumor samples were used as a cut-off
point at univariate analysis. Univariate Cox analysis was
carried out to identify the factors that were significantly
associated with progression-free and overall survival
(Table 3). In the univariate analysis, ERCC1 expression
(P = 0.001), BAG-1 expression (P =0 . 0 0 1 ) ,T N Ms t a g e
(P = 0.007) and metastasis of lymph node (P =0 . 0 0 6 )
were prognostic of progression-free survival. For overall
survival, ERCC1 expression (P = 0.002), BAG-1 expres-
sion (P =0 . 0 0 1 ) ,T N Ms t a g e( P = 0.008) and metastasis
of lymph node (P = 0.007) were also prognostic. None
of the other factors examined were statistically corre-
lated with progression-free or overall survival for
ERCC1, BAG-1 and the other three genes.
Multivariate Cox regression analysis was performed to
evaluate the influence of these genes on the progres-
sion-free survival adjusting for possible confounding fac-
tors. From the results of the univariate analysis, TNM
stage and metastasis of lymph node, also ERCC1 and
BAG-1 were significantly correlated to the progression-
free survival (Table 4). After multivariate analysis,
ERCC1 was statistically significant (P =0 . 0 1 8 )a n dt h e
hazard ratio was 0.0427 (95% CI: 0.211-0.864). BAG-1
was also statistically significant (P = 0.017) and the
hazard ratio was 0.0474 (95% CI: 0.257-0.874). However,
the P-value for TNM stage (P = 0.340, 95% CI: 0.336-
1.457) and lymph node (P = 0.217, 95% CI: 0.299-1.315)
were not statistically significant.
Multivariate Cox regression analysis was also per-
formed for the overall survival. In addition to ERCC1,
BAG-1, TNM stage and metastasis of lymph node
were included in the Cox models. The other gene of
TUBB3, BRCA1 and RRM1, together with the rest of
patients’ and clinical characteristics were not included.
Negative ERCC1 and BAG-1 expression were indepen-
dent and significant predictor of favorable outcome for
Table 2 Primers for gene analysis
Gene Accession Number Primer sequence(5’-3’) Product length Tm
ERCC1 NM_001983.3 Forward 5’-CCCTGGGAATTTGGCGACGTAA-3’ 273 bp 59°C
Reverse 5’-CTCCAGGTACCGCCCAGCTTCC-3’
BAG1 NM_004323.5 Forward 5’-GGCAGCAGTGAACCAGTTG-3’ 242 bp 54.5°C
Reverse 5’-GCTATCTTCTCCACAGACTTCTC-3’
BRCA1 NM_007294.3 Forward 5’-AAGGTTGTTGATGTGGAGGAG-3’ 208 bp 55.6°C
Reverse 5’-CAGAGGTTGAAGATGGTATGTTG-3’
RRM1 NM_001033.3 Forward 5’-TGGCCTTGTACCGATGCTG-3’ 161 bp 57.5°C
Reverse 5’-GCTGCTCTTCCTTTCCTGTGTT-3’
TUBB3 NM_006086.3 Forward 5’-CGGATCAGCGTCTACTAC-3’ 222 bp 49°C
Reverse 5’-CACATCCAGGACCGAATC-3’
b-actin NM_001101.3 Forward 5’-CTCGCGTACTCTCTCTTTCTGG-3’ 334 bp 60°C
Reverse 5’-GCTTACATGTCTCGATCCCACTTAA-3’
Figure 1 The expression of ERCC1, BAG-1, BRCA1, RRM1 and
TUBB3 in NSCLC tissues.1 :b-actin; 2: positive control of ERCC1; 3:
negative control; 4-5: positive and negative expression of ERCC1; 6-
7: positive and negative expression of BAG-1; 8-9: positive and
negative expression of BRCA1; 10-11: positive and negative
expression of RRM1; 12-13: positive and negative expression of
TUBB3.
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hazard ratio of ERCC1 was 0.447 (95% CI: 0.219-
0.911); for BAG-1, with a hazard ratio of 0.486 (95%
CI: 0.262-0.901), whereas TNM stage and metastasis of
lymph node had no significant association. The reason
that TNM staging and lymph node were not associated
with survival in the multivariate analysis might be the
statistical significance of the two characteristics with
survival contained in the other variables (ERCC1 and
BAG-1). The other explanatory reason might be the
limit of sample size.
Correlations between ERCC1, BAG-1, BRCA1, RRM1 and
TUBB3 expression and the kind of adjuvant
chemotherapy
74 of 85 patients received at least two cycles of adjuvant
c h e m o t h e r a p y ,o fw h o m6 6( 8 9 . 2 % )f i n i s h e da tl e a s t4
cycles. The main chemotherapy regimens included gem-
citabine (GEM, 45.9%), vinorelbine (NVB, 39.2%) and
paclitaxel (PTX, 14.9%) combined with cisplatin (DDP)/
carboplatin (CBP).
In 74 patients treated with the regimen of cisplatin/
carboplatin, patients negative for ERCC1 expression had

Figure 2 Immunohistochemical staining of ERCC1 proteins in NLCLC tissues. Expression of ERCC1 protein was detected in the nuclei of
cancer cells. a-f: squamous carcinoma; g-l: adenocarcinoma.
Leng et al. Journal of Experimental & Clinical Cancer Research 2012, 31:25
http://www.jeccr.com/content/31/1/25
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than 42.6 months vs. 13.0 months, P = 0.001) and over-
all (more than 42.6 months vs. 19.7 months, P = 0.001)
survival, compared with those positive for ERCC1
expression (Figures 7, 8). Patients negative for BAG-1
expression also had a significantly longer median pro-
gression-free survival (29.0 months vs. 11.2 months, P =
0.002) and overall survival (32.3 months vs. 15.2
months, P = 0.002), than those positive for BAG-1
expression (Figures 9, 10). Whereas, there was no statis-
tical significance in progression-free and overall survival
to patients with BRCA1 expression (P = 0.129 and P =
0.073, respectively). In those treated with the regimen of
gemcitabine, there was no statistical significance found
in progression-free and overall survival for patients with
RRM1 expression (P =0 . 3 1 0a n dP =0 . 2 9 9 ,r e s p e c -
tively). In the anti-tubulin regimen group of vinorelbine
or paclitaxel, no statistical significance was found in
progression-free and overall survival between the nega-
tive and positive expression of TUBB3 (P =0 . 7 4 5a n dP
= 0.742, respectively); in the same measure, no statistical
significance was found in progression-free and overall
Figure 3 Progression-free survival according to ERCC1
expression (more than 42.6 vs. 15.4 months, P = 0.001).
Figure 4 Overall survival according to ERCC1 expression (more
than 42.6 vs. 20.9 months, P = 0.001).
Figure 5 Progression-free survival according to BAG-1
expression (more than 42.6 vs. 12.9 months, P = 0.001).
Figure 6 Overall survival according to BAG-1 expression (more
than 42.6 vs. 17.0 months, P = 0.001).
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BRCA1 (P = 0.612 and P = 0.389, respectively).
Correlation of ERCC1 and BAG-1 expression
There were 25 cases that expressed both ERCC1 and
BAG-1 and 27 cases that expressed neither. As shown
in Table 5, the correlation was found between ERCC1
and BAG-1 gene expression (P = 0.042, r = 0.247). All
52 patients of both positive and negative expression
were received adjuvant chemotherapy. For both negative
mRNA expression had a significantly longer median
progression-free (more than 42.6 months vs. 8.8 months,
P = 0.000) and overall (more than 42.6 months vs. 17.0
months, P = 0.000) survival, compared with those posi-
tive for both ERCC1 and BAG-1 expression (Figures 11,
12).
Discussion
Along with the development of theory and practice in
treatment of chemotherapy with resected NSCLC, we
have already known the combination of two cytotoxic
drugs, like a platinum and a non-platinum agent, is the
standard first-line treatment of NSCLC patients [12].
However, because of the high rate of toxicity observed
and associated with drug resistance, treatment response
rate and median overall survival are not satisfactory.
This appears to be gene of chemoresistance, which plays
an important role in the after surgery treatment. So,
some markers detection is a key for chemotherapy in
NSCLC patients.
Platinum drugs mainly exert their cytotoxicity by
forming bulky intra-strand platinum-DNA adducts and
inter-strand cross-link of the two DNA strands. Removal
of these adducts from genomic DNA and repair of inter-
strand cross-links in DNA and recombination processes
are mediated by components of different DNA repair
pathways. ERCC1 is a key factor involved in nuclear
excision repair (NER) for platinum induced adducts
[13]. There is observation of platinum resistance in lung
cancer A549 cells lines with high expression of ERCC1
[14], and increased clinical evidence that overexpression
of ERCC1 in NSCLC inhibits platinum efficacy. In addi-
tion to ERCC1 negative tumors appear to benefit from
cisplatin based chemotherapy, it also gains benefit from
overall survival as a prognostic factor [2,15,16]. As a
predictive factor, a phase III trial in NSCLC showed bet-
ter PFS and OS in the low genotypic than in the high
genotypic group, and the patients in the low genotypic
group also had a trend toward a lower risk of progres-
sion than those in the control arm [17]. Although it had
been identified that ERCC1 positive could be associated
with resistance to platinum based chemotherapy, how-
ever, some studies reported that ERCC1 expression had
correlation with improved prognosis [18,19]. This dis-
crepancy may be due to differences of experimental pro-
cessing, regional disparity or technical issues. In our
Table 3 Univariate analysis of Clinicopathological features, tumor markers, and patient survival
Variable PFS HR (95% CI) P value OS HR (95% CI) P value
Gender (Male vs. Female) 1.370 (0.744-2.524) 0.313 1.341 (0.713-2.421) 0.381
Age (≤ 60 vs.>60) 1.433 (0.789-2.604) 0.237 1.450 (0.798-2.635) 0.223
Nationality (The Han vs. The Zhuang) 0.929 (0.480-1.800) 0.827 0.964 (0.497-1.867) 0.912
Histology (Squamous carcinoma vs. Adenocarcinoma) 0.541 (0.267-1.095) 0.088 0.559 (0.276-1.133) 0.106
Differentiation (Well and moderate vs. Poor) 0.992 (0.528-1.866) 0.980 0.953 (0.506-1.795) 0.881
Metastasis lymphatics (Yes vs. No) 0.429 (0.236-0.780) 0.006** 0.435 (0.238-0.793) 0.007**
TNM stage (I+II vs. III+IV) 2.267 (1.257-4.090) 0.007** 2.217 (1.227-4.003) 0.008**
ERCC1 (positive vs. negative) 0.326 (0.165-0.645) 0.001** 0.333 (0.169-0.660) 0.002**
BAG-1 (positive vs. negative) 0.367 (0.202-0.665) 0.001** 0.363 (0.200-0.658) 0.001**
BRCA1 (positive vs. negative) 0.546 (0.270-1.105) 0.093 0.505 (0.250-1.021) 0.057
RRM1 (positive vs. negative) 0.539 (0.314-1.143) 0.120 0.590 (0.309-1.126) 0.110
TUBB3 (positive vs. negative) 0.665 (0.319-1.383) 0.275 0.701 (0.338-1.458) 0.342
** represent P < 0.01
Table 4 Multivariate analysis of Clinicopathological features, tumor markers, and patient survival
Variable PFS HR (95% CI) P value OS HR (95% CI) P value
ERCC1 (positive vs. negative) 0.427 (0.211-0.864) 0.018* 0.447 (0.219-0.911) 0.027*
BAG-1 (positive vs. negative) 0.474 (0.257-0.874) 0.017* 0.486 (0.262-0.901) 0.022*
Metastasis lymphatics (Yes vs. No) 0.627 (0.299-1.315) 0.217 0.654 (0.352-1.370) 0.260
TNM stage (I + II vs. III + IV) 0.699 (0.336-1.457) 0.340 1.442 (0.691-2.984) 0.324
* represent P < 0.05
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than stage I + II (P = 0.006). This was also happened in
lymph node metastasis compared to no metastasis (P =
0.01), which like Ota et al. reported [20]. The available
data indicate ERCC1 positive patients might present a
poor prognosis, and ERCC1 expression might appear to
be an advanced stage event.
The BAG-1, as an anti-apoptotic function, exhibits
positive expression in many malignant tumors. It binds
to the cytosolic domain of the growth factor receptors
on the cell surface, enhancing the protection from cell
death triggered by these receptors. However, it binds to
Bcl-2 and heat shock protein (HSP) and modulates their
function in the cytosol, and it binds to nuclear hormone
receptors for inhibiting hormone-induced apoptosis in
the nucleus [21]. Further exploration shows overexpres-
sion of BAG-1 suppresses activation of caspases and
apoptosis induced by chemotherapeutic agents [22]. As
expected, experiment performed in lung cancer cells
Figure 7 Progression-free survival according to ERCC1
expression which was based on platinum chemotherapy (more
than 42.6 vs. 13.0 months, P = 0.001).
Figure 8 Overall survival according to ERCC1 expression which
was based on platinum chemotherapy (more than 42.6 vs.
19.7 months, P = 0.001).
Figure 9 Progression-free survival according to BAG-1
expression which was based on platinum chemotherapy (29.0
vs. 11.2 months, P = 0.002).
Figure 10 Overall survival according to BAG-1 expression
which was based on platinum chemotherapy (32.3 vs. 15.2
months, P = 0.002).
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cancer cells to cisplatin-induced apoptosis [5]. In this
study, the positive BAG-1 expression correlated signifi-
cantly with progression-free and overall survival in
patients treated by platinum. As we described, current
research has proven expression of BAG-1 indicates poor
prognosis [23]. Whereas, Rorke et al. [24] reported high
expression of BAG-1 may correlate to better prognosis
in NSCLC. The difference between findings may be due
to different choices of treatment and different compo-
nents of data.
BRCA1 is implicated in NER, which was discussed in
the part of ERCC1, it also associates with double-strand
break repair and mismatch repair, indicating its crucial
role in DNA repair [25]. It has been indicated that
BRCA1 presents different sensitivity to different che-
motherapy agent in vitro study. The negative expression
of BRCA1 results in high sensitivity to cisplatin, whereas
its positive expression increases sensitivity to antimicro-
tubule agents [26]. In clinical research, it was found that
patients whose tumors had BRCA1 expression would
have significantly poorer survival and should be
candidates for adjuvant chemotherapy [27]. Median sur-
vival was 11 months for 38 patients with low BRCA1,
treated with cisplatin plus gemcitabine; 9 months for 40
patients with intermediate BRCA1, treated with cisplatin
plus docetaxel; and 11 months for 33 patients with high
BRCA1, treated with docetaxel alone. Two-year survival
was 41.2%, 15.6% and 0%, respectively, which had mani-
fested the potential predictive role of BRCA1 in a recent
non-randomized phase II clinical trial [28]. Our findings
indicate that BRCA1 expression might correlate with OS
and platinum treatment based OS, however, there was
no statistical significance (P = 0.052 vs. P = 0.073).
Nevertheless, the results tend to migrate to statistical
significant directions accompanied extension of follow-
up time and expansion of sample size.
In addition, as the gene sensitive to cisplatin or other
DNA damaging agents, expression of ERCC1 is closely
related to BRCA1, no matter in breast cancer or in
NSCLC [29,30]. But there is not much more studies
indicate correlations between BAG-1. Our findings
demonstrate a strong correlation between ERCC1 and
BAG-1. Therefore, it is plausible that patients with the
expression of ERCC1 and BAG-1 present a poor prog-
nosis and the lack of its expression would receive more
benefit from non platinum based chemotherapy.
As one of the targets of gemcitabine, RRM1 also have
roles in DNA repair systems like ERCC1 and BRCA1. It
encodes the regulatory subunit of ribonucleotide reduction
of ribonucleoside diphosphates to the corresponding deox-
yribonucleotides [31]. In earlier study, it suggested contin-
uous exposure of lung cancer cell lines to increasing
Table 5 Correlation between expression of ERCC1 and
BAG-1
Gene ERCC1
+-
+2 5 8
BAG-1
-2 5 2 7
Figure 11 Progression-free survival according to 52 NSCLC
patients who have both ERCC1 and BAG-1 expression, all of
whom were based on platinum chemotherapy (more than 42.6
vs. 8.8 months, P = 0.000).
Figure 12 Overall survival according to 52 NSCLC patients who
have both ERCC1 and BAG-1 expression, all of whom were
based on platinum chemotherapy (more than 42.6 vs. 17.0
months, P = 0.000).
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of RRM1 [32]. In addition, another research showed
reduced RRM1 expression increased sensitivity to gemcita-
bine in lung cancer cell lines, and found RRM1 expression
in tumor is a major predictor of disease response to gem-
citabine chemotherapy during a prospective phaseII clini-
cal trial with NSCLC [8]. TUBB3 is investigated and
recognized as a role in resistance to antitubulin agents.
The report shows TUBB3 is expressed in high levels in
lung cancer cell lines, and by using RNAi technology, it
was found that TUBB3 mediates sensitivity to paclitaxel in
NSCLC cells, and high levels of TUBB3 expression are
associated with paclitaxel and docetaxel resistance in vitro
[11,33,34]. Our result showed that TUBB3 was more fre-
quently observed in stage I + II than in stage III + IV
patients (P = 0.004). But Recent data suggested expression
of TUBB3 was related to advanced stage NSCLC [35]. In
this study, no correlation of chemotherapy between RRM1
and TUBB3, or the survival of the patients was found. It
might be caused by the limitation of different cycles of
adjuvant chemotherapy taken by patients and other inter-
ferences like number of samples and only one clinical cen-
ter involved in our study.
Conclusions
In summary, to better overcome the problems related to
drug resistance and to improve the clinical outcome of
advanced NSCLC patients, relationship between drug
resistance caused by gene expression and prognosis of
patients received adjuvant chemotherapy must be investi-
gated. Our findings indicate ERCC1 and BAG-1 are prog-
nostic factors for progression-free and overall survival, and
may be predictive biomarkers for platinum based che-
motherapy in NSCLC patients. Accompanied by enlarge-
ment of sample size, BRCA1 might also be an indicator
the above-mentioned. Although the approach of RT-PCR
has a better feasibility and repeatability, and we have qual-
ity control of the laboratory. It remain has many factors
influence the experimentation to cause the false positive
results. Moreover, 85 patients were certainly few and fol-
low-up time was short to be able to conclude firmly on
any of the findings in our study, particularly using multi-
variate analysis. However, because of patients with nega-
tive expression of these genes indeed receive more benefit
from platinum based chemotherapy in our study, the com-
bined detection of the mRNA expression of these genes
might better individualize the efficacy of chemotherapy
and improve survival in this common and vital cancer.
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